It selects 23 serotypes of pneumococci that are the most widely prevalent and invasive. Advanced manufacturing technologies are adopted to improve antigen purity and enhance safety.
This product completed Phase I clinical trials in April 2023. The Phase I clinical trials showed that this product could trigger a strong immunogenic response (in subjects aged 2 years and above), indicating significant vaccine efficacy. The incidence of vaccination-related adverse events (AE) was lower than that in the control group. After the completion of Phase I clinical trials, the process was further improved and optimized through independent research and development. It is planned to initiate Phase III clinical trials in Q4 2025/Q1 2026.

For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.